Morley Research Consortium Expands CRO Offerings
News Nov 25, 2010
The new name, Morley Research Consortium, not only reflects a growth in services offered, but also an expanded management team, which now includes Jane Green, Ph.D., Donald Johnson and Penny Smith, BSN, JD. The Consortium provides a comprehensive scope of services coupled with a high level of effectiveness, skill and customer service that the principals felt was lacking in the industry.
The company's team of highly experienced professionals has successfully managed all phases of clinical trials in a wide variety of therapeutic areas. In addition to comprehensive clinical trial project management services ranging from studies in the earliest stages of development through clinical trials and post-approval research, MRC also provides contract management services encompassing all aspects of the clinical trial contracting and management process.
MRC has become known in the industry for their in-depth knowledge that allows the mitigation of potential risks during clinical trials, as well as for being "trouble-shooters" who can get a problematic trial back on track and turn unprofitable studies into profit centers. The company is a national leader in the research industry, specifically in the area of compliance, audit and management of clinical trials.
MRC frequently works with complex clients with Integrity Holds from the FDA or serious 483s which adversely affect research centers in universities, hospitals, private practices and sponsor companies.
Morley Research Consortium has helped numerous hospitals and private practices create or improve their clinical research programs. MRC also provides research compliance management and auditing for research programs for numerous universities and hospitals nationwide. The company has an extensive database of research sites throughout the U.S. and several international sites for industry-sponsored studies.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE